Quest Diagnostics Key Executives
This section highlights Quest Diagnostics's key executives, including their titles and compensation details.
Find Contacts at Quest Diagnostics
(Showing 0 of )
Quest Diagnostics Earnings
This section highlights Quest Diagnostics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-01-30 | $2.19 | $2.23 |
| Read Transcript | Q3 | 2024 | 2024-10-22 | $2.26 | $2.30 |
| Read Transcript | Q2 | 2024 | 2024-07-23 | $2.34 | $2.35 |
| Read Transcript | Q1 | 2024 | 2024-04-23 | $1.86 | $2.04 |
| Read Transcript | Q4 | 2023 | 2024-02-01 | $2.11 | $2.15 |
| Read Transcript | Q3 | 2023 | 2023-10-24 | $2.19 | $2.22 |
| Read Transcript | Q2 | 2023 | 2023-07-26 | $2.27 | $2.30 |
| Read Transcript | Q1 | 2023 | 2023-04-27 | $1.97 | $2.04 |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
$167.33
Stock Price
$18.57B
Market Cap
56.00K
Employees
Secaucus, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Quest Diagnostics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B |
| Cost of Revenue | $6.63B | $6.29B | $6.45B | $6.58B | $5.80B |
| Gross Profit | $3.24B | $2.96B | $3.43B | $4.21B | $3.63B |
| Gross Profit Ratio | 32.86% | 32.00% | 34.74% | 39.00% | 38.50% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.77B | $1.61B | $1.87B | $1.73B | $1.55B |
| Other Expenses | $128.00M | $- | $131.00M | $101.00M | $112.00M |
| Operating Expenses | $1.93B | $1.76B | $2.00B | $1.83B | $1.66B |
| Cost and Expenses | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B |
| Interest Income | $25.00M | $11.00M | $10.00M | $1.00M | $3.00M |
| Interest Expense | $226.00M | $163.00M | $138.00M | $151.00M | $163.00M |
| Depreciation and Amortization | $493.00M | $439.00M | $437.00M | $408.00M | $361.00M |
| EBITDA | $1.91B | $1.73B | $1.82B | $3.16B | $2.41B |
| EBITDA Ratio | 19.34% | 18.72% | 18.31% | 29.27% | 25.52% |
| Operating Income | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B |
| Operating Income Ratio | 13.63% | 13.64% | 14.45% | 22.07% | 20.89% |
| Total Other Income Expenses Net | $-171.00M | $-132.00M | $-193.00M | $218.00M | $-87.00M |
| Income Before Tax | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B |
| Income Before Tax Ratio | 11.90% | 12.21% | 12.50% | 24.09% | 19.96% |
| Income Tax Expense | $273.00M | $248.00M | $264.00M | $597.00M | $460.00M |
| Net Income | $871.00M | $854.00M | $946.00M | $2.00B | $1.43B |
| Net Income Ratio | 8.82% | 9.23% | 9.57% | 18.49% | 15.16% |
| EPS | $7.80 | $7.59 | $8.12 | $15.90 | $10.68 |
| EPS Diluted | $7.66 | $7.52 | $7.98 | $15.53 | $10.52 |
| Weighted Average Shares Outstanding | 111.00M | 112.00M | 116.00M | 125.00M | 134.00M |
| Weighted Average Shares Outstanding Diluted | 113.00M | 113.00M | 118.00M | 128.00M | 136.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | $2.45B | $2.61B | $2.74B | $2.77B | $2.55B | $2.72B | $3.00B | $2.79B | $1.83B | $1.82B |
| Cost of Revenue | $1.76B | $1.68B | $1.62B | $1.61B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | $1.61B | $1.65B | $1.72B | $1.67B | $1.56B | $1.63B | $1.73B | $1.58B | $1.22B | $1.27B |
| Gross Profit | $858.00M | $811.00M | $776.00M | $755.00M | $740.00M | $754.00M | $792.00M | $771.00M | $758.00M | $868.00M | $842.00M | $965.00M | $1.03B | $1.10B | $985.00M | $1.09B | $1.27B | $1.21B | $606.00M | $552.00M |
| Gross Profit Ratio | 32.74% | 32.60% | 32.40% | 31.90% | 32.30% | 32.90% | 33.90% | 33.10% | 32.50% | 34.90% | 34.30% | 37.00% | 37.40% | 39.80% | 38.60% | 40.20% | 42.27% | 43.29% | 33.17% | 30.30% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $347.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $466.00M | $448.00M | $406.00M | $436.00M | $402.00M | $380.00M | $416.00M | $439.00M | $563.00M | $464.00M | $422.00M | $425.00M | $464.00M | $427.00M | $429.00M | $407.00M | $447.00M | $396.00M | $360.00M | $347.00M |
| Other Expenses | $31.00M | $33.00M | $3.00M | $9.00M | $-27.00M | $-3.00M | $6.00M | $27.00M | $60.00M | $12.00M | $32.00M | $27.00M | $3.00M | $40.00M | $322.00M | $4.00M | $2.00M | $77.00M | $13.00M | $-16.00M |
| Operating Expenses | $497.00M | $481.00M | $406.00M | $436.00M | $429.00M | $412.00M | $444.00M | $466.00M | $623.00M | $476.00M | $454.00M | $452.00M | $490.00M | $452.00M | $452.00M | $434.00M | $474.00M | $488.00M | $323.00M | $377.00M |
| Cost and Expenses | $2.26B | $2.16B | $2.03B | $2.05B | $1.98B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | $2.06B | $2.10B | $2.21B | $2.12B | $2.02B | $2.06B | $2.21B | $2.07B | $1.54B | $1.65B |
| Interest Income | $7.00M | $9.00M | $3.00M | $6.00M | $6.00M | $1.00M | $2.00M | $2.00M | $4.00M | $4.00M | $2.00M | $- | $1.00M | $- | $- | $- | $1.00M | $- | $1.00M | $1.00M |
| Interest Expense | $72.00M | $58.00M | $47.00M | $49.00M | $40.00M | $40.00M | $37.00M | $35.00M | $36.00M | $33.00M | $36.00M | $37.00M | $37.00M | $38.00M | $38.00M | $38.00M | $39.00M | $42.00M | $41.00M | $41.00M |
| Depreciation and Amortization | $135.00M | $125.00M | $117.00M | $116.00M | $109.00M | $111.00M | $112.00M | $107.00M | $116.00M | $108.00M | $107.00M | $106.00M | $106.00M | $101.00M | $100.00M | $101.00M | $98.00M | $89.00M | $89.00M | $85.00M |
| EBITDA | $507.00M | $479.00M | $478.00M | $431.00M | $392.00M | $451.00M | $468.00M | $421.00M | $261.00M | $496.00M | $466.00M | $595.00M | $646.00M | $793.00M | $955.00M | $765.00M | $896.00M | $884.00M | $386.00M | $245.00M |
| EBITDA Ratio | 19.34% | 19.25% | 20.32% | 18.39% | 18.36% | 19.61% | 19.93% | 17.98% | 11.19% | 19.79% | 19.00% | 22.79% | 23.51% | 28.59% | 37.45% | 28.12% | 29.81% | 31.73% | 21.07% | 13.39% |
| Operating Income | $361.00M | $330.00M | $370.00M | $319.00M | $311.00M | $342.00M | $348.00M | $305.00M | $135.00M | $392.00M | $388.00M | $513.00M | $536.00M | $652.00M | $533.00M | $660.00M | $795.00M | $718.00M | $283.00M | $175.00M |
| Operating Income Ratio | 13.77% | 13.26% | 15.44% | 13.48% | 13.59% | 14.90% | 14.88% | 13.08% | 5.79% | 15.77% | 15.82% | 19.65% | 19.53% | 23.50% | 20.90% | 24.26% | 26.48% | 25.77% | 15.49% | 9.60% |
| Total Other Income Expenses Net | $-62.00M | $-34.00M | $-41.00M | $-53.00M | $-30.00M | $-43.00M | $-31.00M | $-28.00M | $-23.00M | $-41.00M | $-65.00M | $-61.00M | $-34.00M | $2.00M | $284.00M | $-34.00M | $-37.00M | $35.00M | $-28.00M | $-57.00M |
| Income Before Tax | $299.00M | $296.00M | $314.00M | $266.00M | $237.00M | $299.00M | $317.00M | $277.00M | $112.00M | $351.00M | $323.00M | $452.00M | $502.00M | $654.00M | $817.00M | $626.00M | $758.00M | $753.00M | $255.00M | $118.00M |
| Income Before Tax Ratio | 11.41% | 11.90% | 13.10% | 11.24% | 10.36% | 13.03% | 13.56% | 11.88% | 4.80% | 14.12% | 13.17% | 17.31% | 18.29% | 23.58% | 32.04% | 23.01% | 25.25% | 27.03% | 13.96% | 6.48% |
| Income Tax Expense | $68.00M | $65.00M | $74.00M | $66.00M | $40.00M | $68.00M | $75.00M | $65.00M | $-4.00M | $81.00M | $77.00M | $110.00M | $114.00M | $153.00M | $177.00M | $153.00M | $191.00M | $177.00M | $66.00M | $26.00M |
| Net Income | $222.00M | $226.00M | $229.00M | $194.00M | $192.00M | $225.00M | $235.00M | $202.00M | $101.00M | $254.00M | $233.00M | $354.00M | $389.00M | $503.00M | $628.00M | $468.00M | $576.00M | $566.00M | $184.00M | $99.00M |
| Net Income Ratio | 8.47% | 9.08% | 9.55% | 8.20% | 8.39% | 9.80% | 10.05% | 8.67% | 4.33% | 10.22% | 9.50% | 13.56% | 14.18% | 18.13% | 24.63% | 17.21% | 19.19% | 20.32% | 10.07% | 5.43% |
| EPS | $2.00 | $2.01 | $2.05 | $1.74 | $1.71 | $1.99 | $2.09 | $1.79 | $0.89 | $2.19 | $1.99 | $2.97 | $3.19 | $4.11 | $5.05 | $3.52 | $4.28 | $4.20 | $1.38 | $0.74 |
| EPS Diluted | $1.96 | $1.99 | $2.04 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.88 | $2.15 | $1.96 | $2.93 | $3.12 | $4.02 | $4.96 | $3.46 | $4.21 | $4.14 | $1.36 | $0.73 |
| Weighted Average Shares Outstanding | 111.00M | 112.00M | 111.00M | 111.00M | 112.00M | 112.00M | 112.00M | 112.00M | 113.00M | 116.00M | 117.00M | 119.00M | 122.00M | 123.00M | 125.00M | 133.00M | 135.00M | 135.00M | 134.00M | 134.00M |
| Weighted Average Shares Outstanding Diluted | 113.00M | 113.00M | 112.00M | 112.00M | 113.00M | 114.00M | 114.00M | 113.00M | 115.00M | 118.00M | 119.00M | 121.00M | 125.00M | 125.00M | 127.00M | 135.00M | 137.00M | 137.00M | 136.00M | 135.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $549.00M | $686.00M | $315.00M | $872.00M | $1.16B |
| Short Term Investments | $- | $- | $- | $44.00M | $- |
| Cash and Short Term Investments | $549.00M | $686.00M | $315.00M | $872.00M | $1.16B |
| Net Receivables | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B |
| Inventory | $188.00M | $190.00M | $192.00M | $208.00M | $223.00M |
| Other Current Assets | $351.00M | $286.00M | $196.00M | $223.00M | $157.00M |
| Total Current Assets | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B |
| Property Plant Equipment Net | $2.76B | $2.42B | $2.35B | $2.30B | $2.23B |
| Goodwill | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B |
| Intangible Assets | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B |
| Goodwill and Intangible Assets | $10.62B | $8.90B | $8.31B | $8.26B | $8.04B |
| Long Term Investments | $123.00M | $135.00M | $132.00M | $141.00M | $521.00M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $255.00M | $198.00M | $144.00M | $163.00M | $176.00M |
| Total Non-Current Assets | $13.76B | $11.65B | $10.94B | $10.87B | $10.97B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B |
| Account Payables | $1.39B | $378.00M | $324.00M | $357.00M | $446.00M |
| Short Term Debt | $775.00M | $456.00M | $247.00M | $269.00M | $296.00M |
| Tax Payables | $- | $- | $2.00M | $10.00M | $43.00M |
| Deferred Revenue | $- | $516.00M | $- | $- | $- |
| Other Current Liabilities | $- | $981.00M | $978.00M | $1.12B | $991.00M |
| Total Current Liabilities | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B |
| Long Term Debt | $6.15B | $4.91B | $4.47B | $4.50B | $4.51B |
| Deferred Revenue Non-Current | $- | $- | $-295.00M | $-290.00M | $-350.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $295.00M | $290.00M | $350.00M |
| Other Non-Current Liabilities | $938.00M | $876.00M | $812.00M | $792.00M | $847.00M |
| Total Non-Current Liabilities | $7.09B | $5.79B | $5.28B | $5.30B | $5.36B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $9.26B | $7.60B | $6.83B | $7.05B | $7.13B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M |
| Retained Earnings | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B |
| Accumulated Other Comprehensive Income Loss | $-88.00M | $-14.00M | $-21.00M | $-14.00M | $-21.00M |
| Other Total Stockholders Equity | $-2.50B | $-2.51B | $-2.38B | $-1.19B | $-2.52B |
| Total Stockholders Equity | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B |
| Total Equity | $6.90B | $6.42B | $6.01B | $6.56B | $6.89B |
| Total Liabilities and Stockholders Equity | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B |
| Minority Interest | $118.00M | $111.00M | $114.00M | $118.00M | $132.00M |
| Total Liabilities and Total Equity | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B |
| Total Investments | $123.00M | $135.00M | $132.00M | $141.00M | $521.00M |
| Total Debt | $6.92B | $5.50B | $4.62B | $4.66B | $4.66B |
| Net Debt | $6.38B | $4.81B | $4.31B | $3.79B | $3.50B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $549.00M | $764.00M | $271.00M | $474.00M | $686.00M | $143.00M | $126.00M | $175.00M | $315.00M | $700.00M | $790.00M | $712.00M | $872.00M | $987.00M | $560.00M | $1.23B | $1.16B | $1.60B | $988.00M | $342.00M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $28.00M | $44.00M | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $549.00M | $764.00M | $271.00M | $474.00M | $686.00M | $143.00M | $126.00M | $175.00M | $315.00M | $700.00M | $790.00M | $712.00M | $872.00M | $987.00M | $560.00M | $1.23B | $1.16B | $1.60B | $988.00M | $342.00M |
| Net Receivables | $1.30B | $1.38B | $1.32B | $1.32B | $1.21B | $1.28B | $1.24B | $1.25B | $1.20B | $1.28B | $1.29B | $1.37B | $1.44B | $1.47B | $1.25B | $1.38B | $1.52B | $1.42B | $1.13B | $972.00M |
| Inventory | $188.00M | $184.00M | $182.00M | $181.00M | $190.00M | $184.00M | $184.00M | $190.00M | $192.00M | $183.00M | $187.00M | $197.00M | $208.00M | $205.00M | $199.00M | $223.00M | $223.00M | $205.00M | $154.00M | $126.00M |
| Other Current Assets | $351.00M | $299.00M | $245.00M | $251.00M | $286.00M | $207.00M | $188.00M | $195.00M | $196.00M | $342.00M | $312.00M | $390.00M | $223.00M | $378.00M | $264.00M | $328.00M | $157.00M | $234.00M | $224.00M | $240.00M |
| Total Current Assets | $2.39B | $2.62B | $2.02B | $2.23B | $2.37B | $1.81B | $1.73B | $1.81B | $1.90B | $2.33B | $2.43B | $2.48B | $2.74B | $2.85B | $2.15B | $3.00B | $3.06B | $3.35B | $2.38B | $1.56B |
| Property Plant Equipment Net | $2.76B | $2.75B | $2.44B | $2.39B | $2.42B | $2.44B | $2.42B | $2.38B | $2.35B | $2.31B | $2.26B | $2.29B | $2.30B | $2.23B | $2.21B | $2.22B | $2.23B | $2.08B | $2.03B | $1.97B |
| Goodwill | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | $7.20B | $7.20B | $7.09B | $7.06B | $7.04B | $6.87B | $6.87B | $6.88B | $6.79B | $6.69B |
| Intangible Assets | $1.76B | $1.72B | $1.20B | $1.19B | $1.17B | $1.22B | $1.25B | $1.08B | $1.09B | $1.11B | $1.14B | $1.17B | $1.17B | $1.15B | $1.17B | $1.14B | $1.17B | $1.19B | $1.14B | $1.14B |
| Goodwill and Intangible Assets | $10.62B | $10.32B | $9.09B | $9.02B | $8.90B | $8.95B | $8.98B | $8.32B | $8.31B | $8.30B | $8.34B | $8.37B | $8.26B | $8.21B | $8.22B | $8.01B | $8.04B | $8.07B | $7.93B | $7.83B |
| Long Term Investments | $123.00M | $125.00M | $126.00M | $133.00M | $135.00M | $130.00M | $135.00M | $128.00M | $132.00M | $138.00M | $147.00M | $155.00M | $141.00M | $124.00M | $111.00M | $527.00M | $521.00M | $480.00M | $495.00M | $496.00M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $255.00M | $272.00M | $216.00M | $182.00M | $198.00M | $149.00M | $152.00M | $150.00M | $144.00M | $132.00M | $137.00M | $155.00M | $163.00M | $155.00M | $176.00M | $170.00M | $176.00M | $164.00M | $158.00M | $188.00M |
| Total Non-Current Assets | $13.76B | $13.47B | $11.86B | $11.73B | $11.65B | $11.67B | $11.69B | $10.98B | $10.94B | $10.89B | $10.89B | $10.97B | $10.87B | $10.72B | $10.71B | $10.93B | $10.97B | $10.79B | $10.61B | $10.49B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $16.15B | $16.09B | $13.88B | $13.95B | $14.02B | $13.48B | $13.43B | $12.79B | $12.84B | $13.22B | $13.31B | $13.44B | $13.61B | $13.57B | $12.86B | $13.93B | $14.03B | $14.14B | $12.99B | $12.05B |
| Account Payables | $287.00M | $1.30B | $1.23B | $1.23B | $378.00M | $1.14B | $1.18B | $1.16B | $324.00M | $1.45B | $1.42B | $1.54B | $357.00M | $1.61B | $1.40B | $1.56B | $446.00M | $1.68B | $1.14B | $976.00M |
| Short Term Debt | $775.00M | $779.00M | $765.00M | $1.06B | $456.00M | $461.00M | $674.00M | $157.00M | $245.00M | $155.00M | $157.00M | $156.00M | $269.00M | $149.00M | $147.00M | $148.00M | $296.00M | $703.00M | $701.00M | $148.00M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $2.00M | $- | $- | $- | $10.00M | $- | $- | $- | $43.00M | $- | $- | $- |
| Deferred Revenue | $- | $- | $-1.41B | $- | $-1.51B | $-1.14B | $-1.18B | $-1.16B | $- | $-1.60B | $-1.57B | $-1.70B | $-357.00M | $-1.61B | $-1.40B | $-1.56B | $196.00M | $-1.54B | $-1.13B | $-975.00M |
| Other Current Liabilities | $1.11B | $16.00M | $16.00M | $13.00M | $981.00M | $14.00M | $20.00M | $38.00M | $980.00M | $- | $- | $- | $1.12B | $- | $- | $- | $991.00M | $9.00M | $6.00M | $5.00M |
| Total Current Liabilities | $2.17B | $2.09B | $2.01B | $2.30B | $1.81B | $1.62B | $1.88B | $1.35B | $1.55B | $1.60B | $1.58B | $1.70B | $1.75B | $1.76B | $1.55B | $1.71B | $1.78B | $2.39B | $1.84B | $1.13B |
| Long Term Debt | $6.15B | $6.19B | $4.32B | $4.29B | $4.91B | $4.45B | $4.29B | $4.46B | $4.47B | $4.49B | $4.48B | $4.51B | $4.50B | $4.50B | $4.50B | $4.51B | $4.51B | $4.45B | $4.44B | $4.44B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-270.00M | $- | $- | $- | $- | $- | $- | $- | $-290.00M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $270.00M | $- | $- | $- | $- | $- | $- | $- | $290.00M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $938.00M | $891.00M | $811.00M | $817.00M | $876.00M | $874.00M | $901.00M | $809.00M | $812.00M | $787.00M | $728.00M | $742.00M | $792.00M | $801.00M | $792.00M | $842.00M | $847.00M | $782.00M | $753.00M | $699.00M |
| Total Non-Current Liabilities | $7.09B | $7.08B | $5.13B | $5.11B | $5.79B | $5.33B | $5.19B | $5.27B | $5.28B | $5.27B | $5.21B | $5.25B | $5.30B | $5.30B | $5.29B | $5.36B | $5.36B | $5.23B | $5.19B | $5.14B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $9.26B | $9.17B | $7.15B | $7.41B | $7.60B | $6.94B | $7.06B | $6.63B | $6.83B | $6.87B | $6.79B | $6.95B | $7.05B | $7.06B | $6.84B | $7.06B | $7.13B | $7.62B | $7.03B | $6.27B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M |
| Retained Earnings | $9.36B | $9.22B | $9.08B | $8.94B | $8.82B | $8.71B | $8.57B | $8.41B | $8.29B | $8.26B | $8.08B | $7.93B | $7.65B | $7.33B | $10.25B | $9.69B | $9.30B | $8.80B | $8.31B | $8.20B |
| Accumulated Other Comprehensive Income Loss | $-88.00M | $-15.00M | $-19.00M | $-16.00M | $-14.00M | $-20.00M | $-16.00M | $-18.00M | $-21.00M | $-31.00M | $-23.00M | $-16.00M | $-14.00M | $-13.00M | $-10.00M | $-31.00M | $-21.00M | $-42.00M | $-55.00M | $-58.00M |
| Other Total Stockholders Equity | $-2.50B | $-2.40B | $-2.45B | $-2.49B | $-2.51B | $-2.27B | $-2.30B | $-2.35B | $-2.38B | $-2.00B | $-1.65B | $-1.53B | $-1.19B | $-930.00M | $-4.34B | $-2.92B | $-2.52B | $-2.36B | $-2.42B | $-2.48B |
| Total Stockholders Equity | $6.78B | $6.81B | $6.62B | $6.43B | $6.31B | $6.42B | $6.25B | $6.05B | $5.89B | $6.24B | $6.41B | $6.38B | $6.44B | $6.39B | $5.90B | $6.75B | $6.76B | $6.40B | $5.83B | $5.66B |
| Total Equity | $6.86B | $6.92B | $6.74B | $6.55B | $6.42B | $6.54B | $6.36B | $6.17B | $6.01B | $6.35B | $6.53B | $6.49B | $6.56B | $6.51B | $6.02B | $6.87B | $6.89B | $6.53B | $5.96B | $5.78B |
| Total Liabilities and Stockholders Equity | $16.15B | $16.09B | $13.88B | $13.95B | $14.02B | $13.48B | $13.43B | $12.79B | $12.84B | $13.22B | $13.31B | $13.44B | $13.61B | $13.57B | $12.86B | $13.93B | $14.03B | $14.14B | $12.99B | $12.05B |
| Minority Interest | $83.00M | $112.00M | $118.00M | $114.00M | $111.00M | $114.00M | $115.00M | $115.00M | $114.00M | $114.00M | $116.00M | $116.00M | $118.00M | $119.00M | $119.00M | $124.00M | $132.00M | $126.00M | $127.00M | $122.00M |
| Total Liabilities and Total Equity | $16.15B | $16.09B | $13.88B | $13.95B | $14.02B | $13.48B | $13.43B | $12.79B | $12.84B | $13.22B | $13.31B | $13.44B | $13.61B | $13.57B | $12.86B | $13.93B | $14.03B | $14.14B | $12.99B | $12.05B |
| Total Investments | $123.00M | $125.00M | $126.00M | $133.00M | $135.00M | $130.00M | $135.00M | $128.00M | $132.00M | $138.00M | $147.00M | $155.00M | $141.00M | $124.00M | $111.00M | $527.00M | $521.00M | $480.00M | $495.00M | $496.00M |
| Total Debt | $6.92B | $6.97B | $5.09B | $5.35B | $5.37B | $4.91B | $4.96B | $4.62B | $4.71B | $4.64B | $4.64B | $4.66B | $4.66B | $4.65B | $4.65B | $4.66B | $4.66B | $5.15B | $5.14B | $4.59B |
| Net Debt | $6.38B | $6.21B | $4.82B | $4.88B | $4.68B | $4.77B | $4.83B | $4.45B | $4.40B | $3.94B | $3.85B | $3.95B | $3.79B | $3.66B | $4.09B | $3.43B | $3.50B | $3.54B | $4.15B | $4.25B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $921.00M | $908.00M | $1.01B | $2.08B | $1.50B |
| Depreciation and Amortization | $493.00M | $439.00M | $437.00M | $408.00M | $361.00M |
| Deferred Income Tax | $13.00M | $-49.00M | $1.00M | $-57.00M | $85.00M |
| Stock Based Compensation | $88.00M | $77.00M | $77.00M | $79.00M | $97.00M |
| Change in Working Capital | $-201.00M | $-145.00M | $119.00M | $87.00M | $22.00M |
| Accounts Receivables | $-71.00M | $-15.00M | $246.00M | $81.00M | $-455.00M |
| Inventory | $- | $- | $- | $-20.00M | $- |
| Accounts Payables | $-67.00M | $-55.00M | $-149.00M | $35.00M | $452.00M |
| Other Working Capital | $-63.00M | $-75.00M | $22.00M | $-9.00M | $3.00M |
| Other Non Cash Items | $20.00M | $42.00M | $69.00M | $-364.00M | $-59.00M |
| Net Cash Provided by Operating Activities | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B |
| Investments in Property Plant and Equipment | $-425.00M | $-408.00M | $-404.00M | $-403.00M | $-418.00M |
| Acquisitions Net | $-2.16B | $-611.00M | $-144.00M | $424.00M | $-330.00M |
| Purchases of Investments | $- | $- | $-5.00M | $-3.00M | $-27.00M |
| Sales Maturities of Investments | $- | $- | $5.00M | $403.00M | $418.00M |
| Other Investing Activities | $41.00M | $-42.00M | $5.00M | $-400.00M | $-415.00M |
| Net Cash Used for Investing Activities | $-2.55B | $-1.06B | $-543.00M | $21.00M | $-772.00M |
| Debt Repayment | $1.54B | $748.00M | $-2.00M | $-2.00M | $-805.00M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-175.00M | $-275.00M | $-1.41B | $-2.20B | $-325.00M |
| Dividends Paid | $-331.00M | $-314.00M | $-305.00M | $-309.00M | $-297.00M |
| Other Financing Activities | $47.00M | $1.00M | $-17.00M | $-30.00M | $160.00M |
| Net Cash Used Provided by Financing Activities | $1.08B | $160.00M | $-1.73B | $-2.54B | $-1.27B |
| Effect of Forex Changes on Cash | $-7.00M | $- | $- | $- | $- |
| Net Change in Cash | $-137.00M | $371.00M | $-557.00M | $-286.00M | $-34.00M |
| Cash at End of Period | $549.00M | $686.00M | $315.00M | $872.00M | $1.16B |
| Cash at Beginning of Period | $686.00M | $315.00M | $872.00M | $1.16B | $1.19B |
| Operating Cash Flow | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B |
| Capital Expenditure | $-425.00M | $-408.00M | $-404.00M | $-403.00M | $-418.00M |
| Free Cash Flow | $909.00M | $864.00M | $1.31B | $1.83B | $1.59B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $222.00M | $237.00M | $228.00M | $193.00M | $192.00M | $237.00M | $249.00M | $217.00M | $116.00M | $276.00M | $250.00M | $373.00M | $413.00M | $527.00M | $650.00M | $490.00M | $609.00M | $591.00M | $193.00M | $106.00M |
| Depreciation and Amortization | $135.00M | $125.00M | $117.00M | $116.00M | $109.00M | $111.00M | $112.00M | $107.00M | $116.00M | $108.00M | $107.00M | $106.00M | $106.00M | $101.00M | $100.00M | $101.00M | $98.00M | $89.00M | $89.00M | $85.00M |
| Deferred Income Tax | $- | $15.00M | $-18.00M | $-18.00M | $-10.00M | $-23.00M | $-12.00M | $-4.00M | $-44.00M | $65.00M | $23.00M | $-43.00M | $30.00M | $2.00M | $-72.00M | $-17.00M | $73.00M | $-11.00M | $9.00M | $14.00M |
| Stock Based Compensation | $27.00M | $19.00M | $20.00M | $22.00M | $19.00M | $18.00M | $16.00M | $24.00M | $22.00M | $18.00M | $19.00M | $18.00M | $19.00M | $21.00M | $21.00M | $18.00M | $34.00M | $32.00M | $17.00M | $14.00M |
| Change in Working Capital | $13.00M | $-42.00M | $-6.00M | $-186.00M | $174.00M | $-148.00M | $81.00M | $-252.00M | $93.00M | $31.00M | $-27.00M | $22.00M | $-82.00M | $-42.00M | $72.00M | $139.00M | $-256.00M | $219.00M | $36.00M | $23.00M |
| Accounts Receivables | $69.00M | $-27.00M | $1.00M | $-114.00M | $71.00M | $-48.00M | $20.00M | $-58.00M | $84.00M | $12.00M | $78.00M | $72.00M | $36.00M | $-220.00M | $127.00M | $138.00M | $-100.00M | $-280.00M | $-160.00M | $85.00M |
| Inventory | $- | $- | $- | $- | $- | $-5.00M | $-6.00M | $- | $- | $- | $- | $- | $-69.00M | $-36.00M | $-78.00M | $163.00M | $-73.00M | $44.00M | $54.00M | $-3.00M |
| Accounts Payables | $- | $9.00M | $41.00M | $-152.00M | $176.00M | $-75.00M | $55.00M | $-211.00M | $20.00M | $32.00M | $-36.00M | $-165.00M | $-1.00M | $235.00M | $-35.00M | $-164.00M | $-62.00M | $472.00M | $89.00M | $-47.00M |
| Other Working Capital | $-56.00M | $-24.00M | $-48.00M | $80.00M | $-73.00M | $-20.00M | $12.00M | $17.00M | $-11.00M | $-13.00M | $-69.00M | $115.00M | $-48.00M | $-21.00M | $58.00M | $2.00M | $-21.00M | $-17.00M | $53.00M | $-12.00M |
| Other Non Cash Items | $67.00M | $2.00M | $231.00M | $547.00M | $43.00M | $12.00M | $-2.00M | $2.00M | $31.00M | $4.00M | $30.00M | $4.00M | $-5.00M | $-48.00M | $-311.00M | $-2.00M | $-17.00M | $-58.00M | $11.00M | $5.00M |
| Net Cash Provided by Operating Activities | $464.00M | $356.00M | $360.00M | $154.00M | $527.00M | $207.00M | $444.00M | $94.00M | $334.00M | $502.00M | $402.00M | $480.00M | $481.00M | $561.00M | $460.00M | $731.00M | $541.00M | $862.00M | $355.00M | $247.00M |
| Investments in Property Plant and Equipment | $-123.00M | $-106.00M | $-92.00M | $-104.00M | $-72.00M | $-105.00M | $-104.00M | $-127.00M | $-147.00M | $-118.00M | $-76.00M | $-63.00M | $-144.00M | $-89.00M | $-84.00M | $-86.00M | $-162.00M | $-91.00M | $-82.00M | $-83.00M |
| Acquisitions Net | $-383.00M | $-1.53B | $-106.00M | $-142.00M | $- | $-2.00M | $-578.00M | $-31.00M | $-38.00M | $- | $-1.00M | $-105.00M | $-80.00M | $735.00M | $-231.00M | $- | $-1.00M | $-101.00M | $-120.00M | $-108.00M |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.00M | $-1.00M | $- | $- | $-3.00M | $-7.00M | $-8.00M | $-1.00M | $-3.00M | $-15.00M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $5.00M | $1.00M | $- | $- | $84.00M | $- | $162.00M | $91.00M | $- | $- |
| Other Investing Activities | $4.00M | $6.00M | $-2.00M | $33.00M | $-42.00M | $- | $- | $- | $11.00M | $- | $-5.00M | $-1.00M | $-3.00M | $-742.00M | $671.00M | $-7.00M | $-159.00M | $-91.00M | $-3.00M | $-15.00M |
| Net Cash Used for Investing Activities | $-502.00M | $-1.63B | $-200.00M | $-213.00M | $-114.00M | $-107.00M | $-682.00M | $-158.00M | $-174.00M | $-118.00M | $-82.00M | $-169.00M | $-227.00M | $-96.00M | $437.00M | $-93.00M | $-168.00M | $-193.00M | $-205.00M | $-206.00M |
| Debt Repayment | $-1.00M | $1.84B | $-301.00M | $- | $471.00M | $-42.00M | $319.00M | $- | $-1.00M | $- | $- | $-1.00M | $- | $-1.00M | $- | $-1.00M | $-552.00M | $-1.00M | $549.00M | $-801.00M |
| Common Stock Issued | $- | $-28.00M | $- | $12.00M | $- | $13.00M | $22.00M | $25.00M | $- | $- | $- | $- | $- | $40.00M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-151.00M | $23.00M | $- | $-23.00M | $-275.00M | $-13.00M | $-22.00M | $-28.00M | $-461.00M | $-374.00M | $-200.00M | $-373.00M | $-289.00M | $- | $-1.50B | $-410.00M | $-250.00M | $- | $- | $-75.00M |
| Dividends Paid | $-84.00M | $-84.00M | $-84.00M | $-79.00M | $-80.00M | $-80.00M | $-80.00M | $-74.00M | $-75.00M | $-78.00M | $-78.00M | $-74.00M | $-77.00M | $-76.00M | $-81.00M | $-75.00M | $-75.00M | $-76.00M | $-75.00M | $-71.00M |
| Other Financing Activities | $66.00M | $9.00M | $6.00M | $-74.00M | $14.00M | $39.00M | $-50.00M | $-2.00M | $-8.00M | $-22.00M | $36.00M | $-23.00M | $-3.00M | $39.00M | $14.00M | $-80.00M | $57.00M | $25.00M | $22.00M | $56.00M |
| Net Cash Used Provided by Financing Activities | $-170.00M | $1.77B | $-363.00M | $-153.00M | $130.00M | $-83.00M | $189.00M | $-76.00M | $-545.00M | $-474.00M | $-242.00M | $-471.00M | $-369.00M | $-38.00M | $-1.57B | $-566.00M | $-820.00M | $-52.00M | $496.00M | $-891.00M |
| Effect of Forex Changes on Cash | $-7.00M | $- | $- | $- | $- | $- | $597.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-215.00M | $493.00M | $-203.00M | $-212.00M | $543.00M | $17.00M | $-49.00M | $-140.00M | $-385.00M | $-90.00M | $78.00M | $-160.00M | $-115.00M | $427.00M | $-670.00M | $72.00M | $-447.00M | $617.00M | $646.00M | $-850.00M |
| Cash at End of Period | $549.00M | $764.00M | $271.00M | $474.00M | $686.00M | $143.00M | $126.00M | $175.00M | $315.00M | $700.00M | $790.00M | $712.00M | $872.00M | $987.00M | $560.00M | $1.23B | $1.16B | $1.60B | $988.00M | $342.00M |
| Cash at Beginning of Period | $764.00M | $271.00M | $474.00M | $686.00M | $143.00M | $126.00M | $175.00M | $315.00M | $700.00M | $790.00M | $712.00M | $872.00M | $987.00M | $560.00M | $1.23B | $1.16B | $1.60B | $988.00M | $342.00M | $1.19B |
| Operating Cash Flow | $464.00M | $356.00M | $360.00M | $154.00M | $527.00M | $207.00M | $444.00M | $94.00M | $334.00M | $502.00M | $402.00M | $480.00M | $481.00M | $561.00M | $460.00M | $731.00M | $541.00M | $862.00M | $355.00M | $247.00M |
| Capital Expenditure | $-123.00M | $-106.00M | $-92.00M | $-104.00M | $-72.00M | $-105.00M | $-104.00M | $-127.00M | $-147.00M | $-118.00M | $-76.00M | $-63.00M | $-144.00M | $-89.00M | $-84.00M | $-86.00M | $-162.00M | $-91.00M | $-82.00M | $-83.00M |
| Free Cash Flow | $341.00M | $250.00M | $268.00M | $50.00M | $455.00M | $102.00M | $340.00M | $-33.00M | $187.00M | $384.00M | $326.00M | $417.00M | $337.00M | $472.00M | $376.00M | $645.00M | $379.00M | $771.00M | $273.00M | $164.00M |
Quest Diagnostics Dividends
Explore Quest Diagnostics's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.98%
Dividend Payout Ratio
38.00%
Dividend Paid & Capex Coverage Ratio
1.76x
Quest Diagnostics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.8 | $0.8 | April 07, 2025 | April 07, 2025 | April 21, 2025 | January 30, 2025 |
| $0.75 | $0.75 | January 14, 2025 | January 14, 2025 | January 29, 2025 | November 12, 2024 |
| $0.75 | $0.75 | October 04, 2024 | October 04, 2024 | October 21, 2024 | August 14, 2024 |
| $0.75 | $0.75 | July 08, 2024 | July 08, 2024 | July 22, 2024 | May 15, 2024 |
| $0.75 | $0.75 | April 05, 2024 | April 08, 2024 | April 22, 2024 | February 01, 2024 |
| $0.71 | $0.71 | January 16, 2024 | January 17, 2024 | January 31, 2024 | November 13, 2023 |
| $0.71 | $0.71 | October 05, 2023 | October 06, 2023 | October 23, 2023 | August 14, 2023 |
| $0.71 | $0.71 | July 10, 2023 | July 11, 2023 | July 25, 2023 | May 16, 2023 |
| $0.71 | $0.71 | April 06, 2023 | April 10, 2023 | April 24, 2023 | February 02, 2023 |
| $0.66 | $0.66 | January 17, 2023 | January 18, 2023 | February 01, 2023 | November 14, 2022 |
| $0.66 | $0.66 | October 03, 2022 | October 04, 2022 | October 19, 2022 | August 10, 2022 |
| $0.66 | $0.66 | July 05, 2022 | July 06, 2022 | July 20, 2022 | May 17, 2022 |
| $0.66 | $0.66 | June 03, 2022 | |||
| $0.66 | $0.66 | April 05, 2022 | April 06, 2022 | April 20, 2022 | February 03, 2022 |
| $0.62 | $0.62 | January 18, 2022 | January 19, 2022 | February 02, 2022 | November 17, 2021 |
| $0.62 | $0.62 | October 04, 2021 | October 05, 2021 | October 20, 2021 | August 16, 2021 |
| $0.62 | $0.62 | July 06, 2021 | July 07, 2021 | July 21, 2021 | May 20, 2021 |
| $0.62 | $0.62 | April 06, 2021 | April 07, 2021 | April 21, 2021 | February 04, 2021 |
| $0.56 | $0.56 | January 19, 2021 | January 20, 2021 | February 03, 2021 | November 18, 2020 |
| $0.56 | $0.56 | October 05, 2020 | October 06, 2020 | October 21, 2020 | August 18, 2020 |
Quest Diagnostics News
Read the latest news about Quest Diagnostics, including recent articles, headlines, and updates.
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day
Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance for full year 2025 SECAUCUS, N.J. , March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company's strategies to drive sustainable growth and deliver long-term shareholder value.
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.
Quest Diagnostics to Host Investor Day on March 19, 2025
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J.
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year
SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.
Why Quest Diagnostics Stock Was Blasting Higher Today
Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day.
Quest Diagnostics Incorporated (DGX) Q4 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conference Call Participants Kevin Caliendo - UBS Patrick Donnelley - Citi Michael Cherny - Leerink Partners Joanna Zhou - Evercore ISI Pito Chickering - Deutsche Bank David Westenberg - Piper Sandler Andrew Brackmann - William Blair Noah Kava - Jefferies Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics Fourth Quarter and Full-Year 2024 Conference Call. At the request of the company, this call is being recorded.
Quest Diagnostics EPS Tops Predictions
Quest Diagnostics (DGX 6.36%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18.
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80 SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024.
Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND , Jan. 27, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J. , Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L.
Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025
SECAUCUS, N.J. , Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DGX.